December 3, 2010. In their newly proposed label, Allergan indicated a “caution” (not a warning) for patients with autoimmune diseases or symptoms, and did NOT mention a family history of those conditions.
Read More »On Medical Treatments & Products
NCHR Testimony at the FDA Advisory Committee Meeting on Lorcaserin
September 16, 2010. The studies are an important reminder that behavior modification is a safe and effective alternative to diet pills. Lorcaserin does not appear to be effective for most patients, and especially not for most African-American or Latino patients. More extensive research is needed on the risks.
Read More »NCHR Testimony at FDA Advisory Committee Meeting on Meridia
September 15, 2010. Meridia is not saving lives and on average harms more patients than it helps. Most people taking Meridia don’t lose much weight, even in the best of circumstances.
Read More »Letter to Thomas Abrams about Continued Misleading Ads for Seroquel XR
August 23, 2010. When we first complained about these ads in January, Seroquel was approved for schizophrenia and for psychosis associated with bipolar disorder.
Read More »Patient, Consumer, and Public Health Coalition Comments to the FDA on “Food Additives; Bisphenol A”
June 4, 2010. There are many unanswered questions about the risks of BPA on human health, especially prenatal exposures, infants, and children.
Read More »